Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

VX-135

- PMLiVE

AZ signs two more deals in cancer immunotherapy

Anglo-Swedish firm pens partnerships with Heptares and Mirati Therapeutics

- PMLiVE

Pharma healthier than it appears, says report

Thomson Reuters research finds global pharma sales will hit $1.3trn by 2018

Bristol-Myers Squibb (BMS) building

BMS signs Opdivo combination pact with Kyowa Hakko Kirin 

Rounds off a week of deals in the immunotherapy space for big pharma

- PMLiVE

Access to new hep C treatments put under the spotlight

NICE plans to restrict use of BMS’ Daklinza follow funding delay for Gilead's Sovaldi

- PMLiVE

FDA approves four new medicines across multiple areas

Sanofi/Regeneron, BMS, AbbVie and Novartis all chalk up major approvals

- PMLiVE

Keytruda cleared for melanoma in Europe

Merck’s new PD-1 drug will compete against rival BMS for market share

Bristol-Myers Squibb (BMS) building

Opdivo gets EU lung cancer nod as kidney cancer trial is halted

Bristol-MyersSquibb's checkpoint inhibitor gains European license for lung cancer

Bristol-Myers Squibb (BMS) building

BMS’ HIV combination Evotaz cleared in Europe

Comes after the firm recently announced it would shelve much of its virology unit

Roche Basel Switzerland

Roche’s breakthrough PD-L1 drug slows cancer growth

Latest positive trial for the firm’s next-gen oncology product atezolizumab

- PMLiVE

Paradigm Comms and Trio Health win healthcare media relations award

Judges said the campaign was a true ‘vehicle for action and change’

- PMLiVE

Vertex wins FDA approval for cystic fibrosis therapy Orkambi

It is the combination therapy’s first regulatory approval

- PMLiVE

BMS drops antiviral research in R&D shake-up

Up to 100 positions set to be lost by the US company’s research shift

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links